Zio Patch

iRhythm Technologies, maker of the Zio XT and Zio AT adhesive heart monitors, announced first quarter financials boasting higher revenue and an improved gross margin during an earnings call for investors earlier this week.

Patients at increased risk for atrial fibrillation wearing iRhythm’s Zio patch — a  continuous ECG monitoring wearable — were more likely to have their atrial fibrillation diagnosed early and receive subsequent preventive care, according to one-year results from a late-breaking study presented at the American College of Cardiology’s annual meeting.

The Scripps Translational Science Institute is working with Aetna and Johnson & Johnson to launch a trial that will test iRhythm's Zio Patch and the Amiigo activity tracker as possible new ways to screen at-risk populations for atrial fibrillation.

iRhythm Technologies, maker of the Zio peel-and-stick wearable heart monitor, has launched a patient-facing companion app on iOS, called myZio, as well as a website, called myZio.

iRhythm Technologies, maker of the Zio patch peel-and-stick heart monitor, has raised $17 million in a round led by Novo A/S, a Danish life sciences investment firm.